公开(公告)号：US20030147904A1

公开(公告)日：2003-08-07

申请号：US10285045

申请日：2002-10-30

发明人： Daniel E. Afar ,  Rene S. Hubert ,  Kahan Leong ,  Arthur B. Raitano ,  Douglas C. Saffran

IPC分类号： A61K039/00 ,  C12Q001/68 ,  G01N033/574 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06 ,  C07K014/47 ,  C07K016/30

CPC分类号： C07K14/705 ,  A01K2217/05 ,  A61K38/1709 ,  C12N2799/026 ,  C12N2799/027 ,  G01N33/57492

摘要： A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.

摘要翻译： 描述了一种新型前列腺肿瘤相关基因（称为24P4C12）及其编码的蛋白质。 24P4C12在前列腺组织异种移植物中高度表达，提供证据表明它在至少一些前列腺癌中被开启。 24P4C12提供了前列腺癌和其他癌症的诊断和/或治疗靶点。

公开(公告)号：US20030147887A1

公开(公告)日：2003-08-07

申请号：US10286927

申请日：2002-11-02

发明人： Shen-Wu Wang ,  Guanghui Hu ,  Yucheng Li ,  Zhengbin Yao

IPC分类号： A61K039/395 ,  C12Q001/68 ,  G01N033/574 ,  A61K039/00 ,  C07K016/30

CPC分类号： G01N33/57407 ,  A61K39/0011 ,  C07K16/3061 ,  C12Q1/6851 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57492

摘要： The present invention provides vaccines, antibodies, and diagnostic tools for the diagnosis and/or treatment of B-cell mediated diseases, particularly B-cell lymphomas.

摘要翻译： 本发明提供用于诊断和/或治疗B细胞介导的疾病，特别是B细胞淋巴瘤的疫苗，抗体和诊断工具。

公开(公告)号：US20030144483A1

公开(公告)日：2003-07-31

申请号：US10229335

申请日：2002-08-26

申请人： Medarex, Inc.

发明人： Philip R. Tempest ,  William J. Harris ,  Frank J. Carr

IPC分类号： C07K016/30

CPC分类号： C07K16/283 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/732

摘要： Humanized antibodies are described which are specific to an Fc receptor (FcR). The humanized antibodies have at least a portion of a complementarity determining region (CDR) derived from a non-human antibody, e.g., murine, with the remaining portions being human in origin. The humanized antibodies can be used therapeutically as is or formulated as bifunctional molecules or immunotoxins.

公开(公告)号：US20030138419A1

公开(公告)日：2003-07-24

申请号：US10295757

申请日：2002-11-15

申请人： The University of Tennessee Research Corporation

发明人： Marko Z. Radic ,  Brian A. Cocca

IPC分类号： A61K039/395 ,  C07K016/30

CPC分类号： C07K16/28 ,  C07K2317/622

摘要： Recombinant antibody single chain variable fragments (scFv) useful for detecting apoptotic cells are disclosed. The antibodies selectively bind on the surface of apoptotic cells. Methods of generating and employing the antibodies are also provided. Methods of detecting modulation of apoptosis are disclosed. Methods of evaluating the efficacy of a candidate therapeutic compound adapted to effect a change in apoptosis are also disclosed. Additionally, a kit for the detection of apoptotic cells is also disclosed.

摘要翻译： 公开了可用于检测凋亡细胞的重组抗体单链可变片段（scFv）。 抗体选择性结合凋亡细胞的表面。 还提供产生和使用抗体的方法。 公开了检测凋亡调节的方法。 还公开了评估适于影响凋亡变化的候选治疗化合物的功效的方法。 此外，还公开了用于检测凋亡细胞的试剂盒。

公开(公告)号：US20030130214A1

公开(公告)日：2003-07-10

申请号：US09791392

申请日：2001-02-23

发明人： Robert Simon Boyd ,  Alasdair Craig Stamps ,  Jonathan Alexander Terrett ,  Kerry Louise Tyson

IPC分类号： A61K048/00 ,  C07H021/04 ,  C12P021/04 ,  A61K039/395 ,  A61K039/00 ,  C07K014/47 ,  C07K016/30

CPC分类号： C07K14/47 ,  A61K9/0019 ,  A61K39/00 ,  A61K47/42 ,  A61K48/00 ,  A61K49/0002 ,  A61K51/1051 ,  A61K2039/505 ,  A61K2039/53 ,  C07K2319/00 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57434 ,  G01N33/57438 ,  G01N2500/00 ,  G01N2800/52

摘要： The present invention provides a protein (BCMP 84) isolated from breast cancer cell line membrane preparations, compositions comprising the protein, including vaccines and antibodies which are immunospecific for the protein. The use of an active agent selected from the protein, corresponding nucleic acids, antibodies and the like, including pharmaceutical compositions, in the diagnosis, screening, treatment and prophylaxis of cancers including breast cancer is also provided.

摘要翻译： 本发明提供从乳腺癌细胞系膜制剂中分离的蛋白质（BCMP84），包含蛋白质的组合物，包括针对蛋白质具有免疫特异性的疫苗和抗体。 还提供了选自蛋白质，相应的核酸，抗体等的活性剂（包括药物组合物）在包括乳腺癌的癌症的诊断，筛选，治疗和预防中的用途。

公开(公告)号：US20030124609A1

公开(公告)日：2003-07-03

申请号：US10328704

申请日：2002-12-23

申请人： Incyte Genomics, Inc.

发明人： Michael G. Walker

IPC分类号： C12Q001/68 ,  G01N033/574 ,  A01K067/00 ,  C12P021/02 ,  C12N005/06 ,  C07K014/705 ,  C07K016/30

CPC分类号： C12Q1/6883 ,  C07K14/47 ,  C12Q2600/158

摘要： The invention provides a mammalian cDNA which encodes a mammalian Ankrd2V. It also provides for the use of the cDNA, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of muscle disorders such as muscle hypertrophy and particularly clear cell sarcoma. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic model system.

公开(公告)号：US20030113332A1

公开(公告)日：2003-06-19

申请号：US10021741

申请日：2001-12-12

申请人： University of North Texas Health Science Center at Fort Worth

发明人： Porunellor A. Mathew ,  Kent Boles

IPC分类号： C12Q001/68 ,  C07H021/04 ,  C12P021/04 ,  A61K039/395 ,  C07K014/705 ,  C07K016/30

CPC分类号： C07K16/2806 ,  A61K2039/505 ,  C07K14/70507 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/30

摘要： The present invention relates to nucleic acid molecules encoding cell surface receptors on immune cells and the characteristic peptides that comprise these receptors. More specifically, the present invention concerns the use of synthetic and recombinant peptides comprising natural killer (nullNKnull) cell surface receptors. The synthetic and recombinant peptides are used to generate monoclonal antibodies that bind a specific NK cell surface receptor called CS1. The binding of the monoclonal antibody to the NK cell surface receptor leads to NK cell activation. In a particular embodiments of the present invention, the monoclonal antibodies are utilized in a method that inhibits the growth of tumor cells.

摘要翻译： 本发明涉及编码免疫细胞上的细胞表面受体的核酸分子和包含这些受体的特征性肽。 更具体地，本发明涉及包含天然杀伤（“NK”）细胞表面受体的合成和重组肽的用途。 合成和重组肽用于产生结合称为CS1的特异性NK细胞表面受体的单克隆抗体。 单克隆抗体与NK细胞表面受体的结合导致NK细胞活化。 在本发明的具体实施方案中，单克隆抗体用于抑制肿瘤细胞生长的方法。

公开(公告)号：US20030103979A1

公开(公告)日：2003-06-05

申请号：US09988013

申请日：2001-11-16

发明人： Shui-on Leung ,  Hans Hansen

IPC分类号： G01N033/574 ,  C07H021/04 ,  A61K039/395 ,  C12P021/02 ,  C12N005/06 ,  C07K014/74 ,  C07K016/30

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/77 ,  C07K2319/00

摘要： A chimeric LL2 monoclonal antibody is described in which the complementarity determining regions (CDRs) of the light and heavy chains of the murine LL2 anti-B-lymphoma, anti-leukemia cell monoclonal antibody has been recombinantly joined to the human kappa and IgG1 constant region domains, respectively, which retains the immunospecificity and B-cell lymphoma and leukemia cell internalization capacity of the parental murine LL2 monoclonal antibody, and which has the potential of exhibiting reduced human anti-mouse antibody production activity. A humanized LL2 monoclonal antibody is described in which the CDRs of the light and heavy chains have been recombinantly joined to a framework sequence of human light and heavy chains variable regions, respectively, and subsequently linked to human kappa and IgG1 constant region domains, respectively, which retains the immunospecificity and B-lymphoma and leukemia cell internalization capacities of the parental murine and chimeric LL2 monoclonal antibodies, and which has the potential for exhibiting reduced human anti-mouse antibody production activity. Vectors for producing recombinant chimeric and humanized chimeric monoclonal antibodies are provided. Isolated DNAs encoding the amino acid sequences of the LL2 variable light and heavy chain and CDR framework regions are described. Conjugates of chimeric and humanized chimeric LL2 antibodies with cytotoxic agents or labels find use in therapy and diagnosis of B-cell lymphomas and leukemias.

公开(公告)号：US20030100058A1

公开(公告)日：2003-05-29

申请号：US10067800

申请日：2002-02-08

申请人： Human Genome Sciences, Inc.

发明人： Viktor Roschke ,  Craig A. Rosen ,  Steven M. Ruben

IPC分类号： C12P021/02 ,  C07H021/04 ,  C12N005/06 ,  C07K016/30

CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/24 ,  C07K16/2866 ,  C07K2319/00 ,  C12N2799/026

摘要： The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

摘要翻译： 本发明涉及一种称为人G蛋白趋化因子受体（CCR5）HDGNR10的新型人类蛋白质，以及编码该蛋白质的分离的多核苷酸。 本发明还涉及结合人G蛋白趋化因子受体（CCR5）HDGNR10的人抗体和编码那些抗体的多核苷酸。 还提供了用于产生人G蛋白趋化因子受体（CCR5）HDGNR10和人抗人G蛋白趋化因子受体（CCR5）HDGNR10抗体的载体，宿主细胞，抗体和重组方法。 本发明还涉及用于诊断和治疗与该新型人蛋白质和这些新型人抗体相关的疾病，病症和/或病症的诊断和治疗方法。

公开(公告)号：US20030044959A1

公开(公告)日：2003-03-06

申请号：US09988626

申请日：2001-11-20

申请人： Myriad Genetics, Inc.

发明人： Sean V. Tavtigian ,  David H.F. Teng ,  Jacques Simard ,  Johanna M. Rommens

IPC分类号： C12N009/64 ,  C12P021/04 ,  C07K016/30

CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K14/4748 ,  C07K16/3069 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156

摘要： The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention farther relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the HPC2 gene, (including gene therapy, protein replacement therapy, protein mimetics, and inhibitors). The invention further relates to the screening of drugs for cancer therapy. The invention also relates to the screening of the HPC2 gene for mutations, which are useful for diagnosing the predisposition to prostate cancer. In addition, the invention relates to a paralog of human HPC2, the paralog being named ELAC1, and to orthologs of human HPC2, these being mouse Elac2, chimpanzee Elac2 and gorilla Elac2.

摘要翻译： 本发明一般涉及人类遗传学领域。 具体地，本发明涉及用于分离和检测人前列腺癌易感基因（HPC2）的方法和材料，其一些等位基因导致癌症易感性，特别是前列腺癌。 更具体地，本发明涉及HPC2基因中的种系突变及其在诊断前列腺癌易感性中的用途。 本发明还涉及带有HPC2基因有害等位基因的个体的症状前症状。 本发明进一步涉及人前列腺癌中HPC2基因的体细胞突变及其在人前列腺癌诊断和预后中的应用。 此外，本发明涉及其他人类癌症中HPC2基因中的体细胞突变及其在人类癌症的诊断和预后中的应用。 本发明还涉及在HPC2基因中具有突变（包括基因治疗，蛋白质替代疗法，蛋白质模拟物和抑制剂）的人类癌症的治疗。 本发明还涉及用于癌症治疗的药物的筛选。 本发明还涉及用于突变的HPC2基因的筛选，其可用于诊断前列腺癌的倾向。 此外，本发明涉及人HPC2，旁系同源异型片段命名为ELAC1的旁系同源物，以及人HPC2的直向同源物，这些是人ElC2，黑猩猩Elac2和大猩猩Elac2。